

SAFETY DATA SHEET

SECTION 1 : IDENTIFICATION

Product Name: Potassium Chloride Injection, Solution for Infusion (10 mEq, 20 mEq, & 40 mEq)
Synonyms: Potassium Chloride Injection (freeflex®)
Distributor Name: Fresenius Kabi USA, LLC
Address: Three Corporate Drive
 Lake Zurich, Illinois 60047
General Phone Number: (847) 550-2300
Customer Service Phone Number: (888) 386-1300
Health Issues Information: (800) 551-7176
SDS Creation Date: March 23, 2022
SDS Revision Date: March 18, 2024

SECTION 2 : HAZARD(S) IDENTIFICATION

GHS Pictograms:



Signal Word:

WARNING.

GHS Class:

Eye Irritation. Category 2.
Skin Irritation. Category 2.

Hazard Statements:

Causes serious eye irritation.
Causes skin irritation.

Precautionary Statements:

Wash hands thoroughly after handling.
Wear protective gloves/protective clothing/eye protection/face protection.
IF ON SKIN: Wash with plenty of water.
IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
Specific treatment (see ... on this label).
If skin irritation occurs: Get medical advice/attention.
If eye irritation persists: Get medical advice/attention.
Take off contaminated clothing and wash it before reuse.

Emergency Overview:

This product is intended for therapeutic use only when prescribed by a physician. Potential adverse reactions from prescribed doses and overdoses are described in the package insert.

Route of Exposure:

Inhalation Ingestion Eye contact Skin Absorption. Injection.

Potential Health Effects:

Eye:

Contact with eyes may cause irritation.

Signs/Symptoms:

Side effects from therapeutic doses include: Nausea, vomiting, abdominal pain, and diarrhea. Reactions that may occur because of the solution or the technique of administration include: Febrile response, infection at the injection site, venous thrombosis or phlebitis extending from the site of injection, extravasation, hypervolemia, and hyperkalemia.

Aggravation of Pre-Existing Conditions:

In patients with renal insufficiency, administration of potassium chloride may cause potassium intoxication and life threatening hyperkalemia.

Potassium Chloride

Signs/Symptoms:

Signs and symptoms of potassium intoxication include: Paresthesias of the extremities, flaccid paralysis, listlessness, mental confusion, weakness and heaviness of the legs, hypotension, cardiac arrhythmias, heart block, electrocardiographic abnormalities, and cardiac arrest.

SECTION 3 : COMPOSITION/INFORMATION ON INGREDIENTS

Chemical Name	CAS#	Ingredient Percent	EC Num.
Potassium Chloride	7447-40-7	14.9; 7.46; 29.8 mg/mL	
Water for Injection	7732-18-5	Quantity Sufficient	

SECTION 4 : FIRST AID MEASURES

Eye Contact:	Immediately flush eyes with plenty of water for at least 15 to 20 minutes. Ensure adequate flushing of the eyes by separating the eyelids with fingers. Get immediate medical attention.
Skin Contact:	Immediately wash skin with plenty of soap and water for 15 to 20 minutes, while removing contaminated clothing and shoes. Get medical attention if irritation develops or persists.
Inhalation:	If inhaled, remove to fresh air. If not breathing, give artificial respiration or give oxygen by trained personnel. Seek immediate medical attention.
Ingestion:	If conscious, flush mouth out with water immediately. Call a physician or poison control center immediately. Do not induce vomiting unless directed to do so by medical personnel. Never give anything by mouth to an unconscious person.
Other First Aid:	For Adverse Event Information, please call (800) 551-7176.

SECTION 5 : FIRE FIGHTING MEASURES

Flash Point:	200 °F
Flash Point Method:	closed cup.
Auto Ignition Temperature:	Not established.
Lower Flammable/Explosive Limit:	Not established.
Upper Flammable/Explosive Limit:	Not established.
Fire Fighting Instructions:	Evacuate area of unprotected personnel. Use cold water spray to cool fire exposed containers to minimize risk of rupture. Do not enter confined fire space without full protective gear. If possible, contain fire run-off water.
Extinguishing Media:	Use alcohol resistant foam, carbon dioxide, dry chemical, or water fog or spray when fighting fires involving this material. Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Protective Equipment:	As in any fire, wear Self-Contained Breathing Apparatus (SCBA), MSHA/NIOSH (approved or equivalent) and full protective gear.
Hazardous Combustion Byproducts:	Thermal decomposition products may include smoke and toxic fumes. Oxides of carbon, oxides of nitrogen and other organic substances may be formed. Other undetermined low molecular weight hydrocarbon compounds may be released in small quantities depending upon specific conditions of combustion.

SECTION 6 : ACCIDENTAL RELEASE MEASURES

Personal Precautions:	Evacuate area and keep unnecessary and unprotected personnel from entering the spill area. Avoid personal contact and breathing vapors or mists. Use proper personal protective equipment as listed in Section 8.
Environmental Precautions:	Avoid runoff into storm sewers, ditches, and waterways.
Methods for containment:	Contain spills with an inert absorbent material such as soil, sand or oil dry.
Methods for cleanup:	Absorb spill with inert material (e.g., dry sand or earth), then place in a chemical waste container. After removal, flush spill area with soap and water to remove trace residue.

SECTION 7 : HANDLING and STORAGE

Handling:	When handling pharmaceutical products, avoid all contact and inhalation of vapor, mists and/or fumes. Use with adequate ventilation. Use only in accordance with directions.
Storage:	Store at controlled room temperature 20 to 25°C (68 to 77°F). [See USP Controlled Room Temperature].
Work Practices:	Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower.
Hygiene Practices:	Wash thoroughly after handling. Avoid contact with eyes and skin. Avoid inhaling vapor or mist.

SECTION 8: EXPOSURE CONTROLS, PERSONAL PROTECTION

Engineering Controls:	General ventilation is sufficient if this product is being used in a controlled medical setting (clinic, hospital, medical office) for its sole intended parenteral (injection) purpose. Otherwise, use appropriate engineering control such as process enclosures, local exhaust ventilation, or other engineering controls including use of a biosafety cabinet / fume hood to control airborne levels below recommended exposure limits.
Eye/Face Protection:	Chemical splash goggles. Wear a face shield also when splash hazard exist.
Skin Protection Description:	Protective laboratory coat, apron, or disposable garment recommended.
Hand Protection Description:	Wear appropriate protective gloves. Consult glove manufacturer's data for permeability data. Nitrile rubber or natural rubber gloves are recommended.

Respiratory Protection: No personal respiratory protective equipment is normally required when this product is being used/administered by a licensed healthcare practitioner (i.e. an end-user such as a clinician / doctor / nurse) for its sole intended parenteral (injection) purpose in a controlled medical setting. The need for respiratory protection will vary according to the airborne concentrations and environmental conditions. A NIOSH approved air-purifying respirator with an organic vapor cartridge or canister may be permissible under certain circumstances. Consult the NIOSH web site (<http://www.cdc.gov/niosh/npptl/topics/respirators/>) for a list of respirator types and approved suppliers.

Other Protective: Consult with local procedures for selection, training, inspection and maintenance of the personal protective equipment.

EXPOSURE GUIDELINES

SECTION 9 : PHYSICAL and CHEMICAL PROPERTIES

Physical State: Liquid solution.
Color: Colorless.
Odor: Odorless.
Boiling Point: Not established.
Melting Point: 773°C
Solubility: Soluble. in water.
Vapor Density: Not established.
Vapor Pressure: Not established.
Percent Volatile: Not established.
pH: 4.0 - 8.0
Molecular Formula: Mixture
Molecular Weight: 74.55
Flash Point: 200 °F
Flash Point Method: closed cup.
Auto Ignition Temperature: Not established.

SECTION 10 : STABILITY and REACTIVITY

Chemical Stability: Stable under normal temperatures and pressures.
Hazardous Polymerization: Not reported.
Conditions to Avoid: No conditions contributing to instability are known to exist for normal handling of this product.

SECTION 11 : TOXICOLOGICAL INFORMATION

Potassium Chloride:

RTECS Number: TS8050000
Eye: Eye - Rabbit Standard Draize test.: 500 mg/24H
Ingestion: Oral - Mouse LD50: 1500 mg/kg [Details of toxic effects not reported other than lethal dose value]
Oral - Rat LD50: 2600 mg/kg [Details of toxic effects not reported other than lethal dose value]
Other Toxicological Information: Intravenous. - Rat LD50: 142 mg/kg [Behavioral - convulsions or effect on seizure threshold Lungs, Thorax, or Respiration - dyspnea]
Intravenous. - Mouse LD50: 117 mg/kg [Details of toxic effects not reported other than lethal dose value]
Intravenous. - Guinea pig LDLo: 77 mg/kg [Details of toxic effects not reported other than lethal dose value]
Intravenous. - Rat LD50: 142 mg/kg [Details of toxic effects not reported other than lethal dose value]
Subcutaneous - Guinea pig LDLo: 2550 mg/kg [Details of toxic effects not reported other than lethal dose value]
Intraperitoneal. - Mouse LD50: 620 mg/kg [Details of toxic effects not reported other than lethal dose value]
Intraperitoneal. - Guinea pig LDLo: 900 mg/kg [Behavioral - changes in motor activity (specific assay) Behavioral - coma Lungs, Thorax, or Respiration - other changes]
Intraperitoneal. - Rat LD50: 660 mg/kg [Details of toxic effects not reported other than lethal dose value]

SECTION 12 : ECOLOGICAL INFORMATION

Ecotoxicity: No ecotoxicity data was found for the product.
Environmental Stability: No environmental information found for this product.

SECTION 13 : DISPOSAL CONSIDERATIONS

SECTION 14 : TRANSPORT INFORMATION

DOT Shipping Name: Not Regulated.
DOT UN Number: Not Regulated.

SECTION 15 : REGULATORY INFORMATION

Potassium Chloride :

TSCA Inventory Status: Listed
EINECS Number: 231-211-8
Canada DSL: Listed

SECTION 16 : ADDITIONAL INFORMATION

HMIS Ratings:

HMIS Health Hazard: 1
HMIS Fire Hazard: 0
HMIS Reactivity: 0
HMIS Personal Protection: X

SDS Creation Date: March 23, 2022

SDS Revision Date: March 18, 2024

SDS Revision Notes: Overall SDS review - no changes. Removed former co-manufacturer. Added product synonym name.

Disclaimer:

The information contained herein pertains to this material. It is the responsibility of each individual party to determine for themselves the proper means of handling and using these materials based on their purpose and intended use. Fresenius-Kabi assumes no liability resulting from the use of or reliance upon the information contained in this material safety data sheet. This material safety data sheet does not constitute the guaranty or specifications of the product.

Copyright© 1996-2018 Enviance. All Rights Reserved.